Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts
Zhouling Xie1, Shuzeng Hou1, Xiaoxiao Yang1
1Department of Pharmaceutical Sciences and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Hefei 230009, P. R. China.
Abstract:
Inhibition of cyclin-dependent kinases (CDKs) has become an effective therapeutic strategy for treating various diseases, especially cancer. Over almost three decades, although great efforts have been made to discover CDK inhibitors, many of which have entered clinical trials, only four CDK inhibitors have been approved. In the process of CDK inhibitor development, many difficulties and misunderstandings have hampered their discovery and clinical applications, which mainly include inadequate understanding of the biological functions of CDKs, less attention paid to pan- and multi-CDK inhibitors, nonideal isoform selectivity of developed selective CDK inhibitors, overlooking the metabolic stability of early discovered CDK inhibitors, no effective resistance solutions, and a lack of available combination therapy and effective biomarkers for CDK therapies. After reviewing the mechanisms of CDKs and the research progress of CDK inhibitors, this perspective summarizes and discusses these difficulties or lessons, hoping to facilitate the successful discovery of more useful CDK inhibitors.
Insights
Cyclin-dependent kinase (CDK) inhibitors show promise for cancer therapy, but development faces challenges. Addressing these hurdles is key to discovering more effective CDK inhibitors for clinical use.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Cyclin-dependent kinases (CDKs) are crucial regulators of the cell cycle, making them attractive therapeutic targets, particularly in oncology.
- Despite extensive research and numerous clinical trials, only a limited number of CDK inhibitors have gained regulatory approval.
- Significant challenges persist in the development and clinical application of CDK inhibitors.
Purpose of the Study:
- To review the mechanisms of CDKs and the progress in developing CDK inhibitors.
- To identify and discuss the key difficulties and lessons learned in the field of CDK inhibitor discovery and application.
- To provide insights that may facilitate the development of more effective CDK inhibitors.
Main Methods:
- Literature review of CDK mechanisms and inhibitor research.
- Analysis of challenges in CDK inhibitor development, including biological understanding, inhibitor design, and clinical translation.
- Discussion of past difficulties to inform future research directions.
Main Results:
- Several factors impede CDK inhibitor development: insufficient understanding of CDK functions, limited focus on pan- and multi-CDK inhibitors, suboptimal isoform selectivity, overlooked metabolic stability, lack of resistance strategies, and absence of effective combination therapies and biomarkers.
- Only four CDK inhibitors have been approved despite decades of research.
Conclusions:
- Overcoming the identified challenges is essential for advancing CDK inhibitor therapies.
- A deeper understanding of CDK biology and strategic development approaches are needed to improve clinical outcomes.
- This perspective aims to guide future research towards the successful discovery of novel and effective CDK inhibitors.
Related Concept Videos
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:34Inhibition of Cdk Activity
01:26Drug Discovery: Overview
02:39Positive Regulator Molecules
00:50Anaphase Promoting Complex
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...